Cognition initiates CT1812 trial in U.S.

Cognition Therapeutics has initiated testing of CT1812 in clinical trials in the United States.
CT1812, a proprietary first-in-class small molecule therapeutic that is administered orally, is being developed by Cognition to treat Alzheimer’s disease.
"The initiation of U.S. clinical testing of CT 1812 represents an important milestone for Cognition as we expand our understanding of the molecule's potential for the treatment of individuals with Alzheimer's disease," Cognition President and CEO Kenneth Moch said. "CT1812's unique mechanism of action, coupled with its high bioavailability and significant penetration across the blood brain barrier, has the potential to differentiate the molecule from all other compounds currently under development in this important therapeutic area."
The first patient in the U.S. has been dosed with CT1812, which will support the testing of Alzheimer’s patients in Australia.